BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

New CEO Search for Ground Breaking Molecular Diagnostics Business, D3 Technologies Ltd


6/3/2009 8:50:09 AM

Bookmark and Share

Glasgow, Scotland, June 3, 2009 -- D3 Technologies Ltd, a world leading provider of trace level detection technologies based on the exploitation of Surface Enhanced Raman Spectroscopy (SERS) and surface enhanced resonance Raman scattering (SERRS), today announced that it has initiated a search for a new Chief Executive Officer. The Company’s current CEO, Professor Ewen Smith, will continue to serve in his current position during the search process before he stands down later this year, thus ensuring an orderly transition during an exciting period of development in the molecular diagnostics market.

The Company is seeking a high calibre inspirational individual, with international experience of new product development and marketing of clinical molecular diagnostics products, to lead D3 Technologies as it moves towards the international launch of its first in-vitro diagnostic (IVD) products. With a clear vision of establishing D3 Technologies as a global player in the field of molecular diagnostics for human infectious diseases, the Chairman and Board of Directors would expect that candidates for the position have a sophisticated working knowledge of healthcare regulation within Europe and the USA, and proven abilities in driving technology commercialisation.

Speaking about the search for his successor, Professor Smith said, “Since the successful spin-out of D3 Technologies from the University of Strathclyde in July 2007 it has been a wonderfully stimulating experience to guide a highly professional multi-disciplinary team of molecular biologists, chemists, physicists, material scientists and engineers, all working towards the development of improved DNA-based diagnostic tests to detect diseases, or the genetic predisposition to diseases. The significant investment from a world-class company such as Renishaw, has given us a solid financial footing and access to the latest in Raman spectroscopy technologies.”

He continued, “I am delighted that the new technology is successful and remain fully committed to the D3 concept. I think that at this time a CEO with commercial skills to take the product to market would be beneficial for D3 and for that reason intend to stand down.”

“Ewen Smith has done a great job as Chief Executive Officer”, said Geoff McFarland, Chairman of D3 Technologies and Board member of parent company, Renishaw plc. “He led the award-winning spin-out in 2007 and the successful purchase of the analytical business unit of Mesophotonics Limited, acquiring the strategically important Klarite™ substrate technology. With the additional investment that he negotiated with Renishaw, the Company has a solid platform from which to launch a globally successful molecular diagnostics business.”

Interested candidates are invited to write in confidence to Peter Bowler, Renishaw’s Group Human Resources Manager

About D3 Technologies Ltd D3 Technologies Ltd is a fast-growing pioneer in trace level detection technologies based on the exploitation of Surface Enhanced Raman Spectroscopy (SERS) and surface enhanced resonance Raman scattering (SERRS). Formed in 2007 by combining world-class nanometrology expertise from the University of Strathclyde with unique Klarite® substrate technology, D3 Technologies is applying its novel techniques to a diverse range of fields including medical diagnostics, analytical applications, security and bio-defence, and forensic science. Based at purpose-built laboratories and offices in Glasgow, Scotland, the company is part of the Renishaw Group, a world-leader in engineering, medical device and spectroscopy technologies.

Further information is available at www.d3technologies.co.uk

About Professor Ewen Smith Professor Smith is a spectroscopist and inorganic chemist with a long track record of research in Raman and surface enhanced resonance Raman scattering (SERRS). Before joining D3 Technologies he was a full time academic at Strathclyde University where he had periods of office as Head of Inorganic Chemistry and Head of Department. He still retains a part time research position at Strathclyde. He is a Fellow of the Royal Society of Edinburgh and the Royal Society of Chemistry, and was awarded a DSc from Glasgow University in 1983. He has close to 300 published papers and has also co-authored a book entitled ‘Modern Raman Spectroscopy A Practical Approach’.


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->